Focus
biogen
Controversial Alzheimer’s Drug Aduhelm Dropped by Drugmaker After Doubtful Data and Denied Coverage
The drug was discontinued by Biogen after inconsistent trial data, concerning side effects including brain swelling, and poor financial outlook.
